Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CFRX NASDAQ:EQ NASDAQ:LPTX NASDAQ:ORMP NASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsEQEquillium$1.29-6.5%$1.53$0.27▼$2.35$76.76M1.533.03 million shs157,959 shsLPTXLeap Therapeutics$0.46-5.9%$0.40$0.22▼$4.79$19.02M-0.052.29 million shs357,143 shsORMPOramed Pharmaceuticals$2.28-2.7%$2.31$1.82▼$3.09$93.33M1.62133,900 shs15,171 shsPRPHProPhase Labs$0.41-19.7%$0.43$0.22▼$2.45$16.78M-0.625.89 million shs3.85 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCFRXContraFect0.00%0.00%0.00%0.00%0.00%EQEquillium-5.48%+11.29%-5.48%+234.95%+23.21%LPTXLeap Therapeutics-7.08%-21.79%+67.56%+35.95%-83.70%ORMPOramed Pharmaceuticals+2.18%-0.85%0.00%+1.74%-0.43%PRPHProPhase Labs-3.42%-2.80%+31.81%+17.45%-78.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsEQEquillium$1.29-6.5%$1.53$0.27▼$2.35$76.76M1.533.03 million shs157,959 shsLPTXLeap Therapeutics$0.46-5.9%$0.40$0.22▼$4.79$19.02M-0.052.29 million shs357,143 shsORMPOramed Pharmaceuticals$2.28-2.7%$2.31$1.82▼$3.09$93.33M1.62133,900 shs15,171 shsPRPHProPhase Labs$0.41-19.7%$0.43$0.22▼$2.45$16.78M-0.625.89 million shs3.85 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCFRXContraFect0.00%0.00%0.00%0.00%0.00%EQEquillium-5.48%+11.29%-5.48%+234.95%+23.21%LPTXLeap Therapeutics-7.08%-21.79%+67.56%+35.95%-83.70%ORMPOramed Pharmaceuticals+2.18%-0.85%0.00%+1.74%-0.43%PRPHProPhase Labs-3.42%-2.80%+31.81%+17.45%-78.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCFRXContraFect 0.00N/AN/AN/AEQEquillium 1.67Reduce$1.00-22.48% DownsideLPTXLeap Therapeutics 1.75Reduce$3.38638.51% UpsideORMPOramed Pharmaceuticals 1.00SellN/AN/APRPHProPhase Labs 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest EQ, CFRX, PRPH, LPTX, and ORMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025EQEquilliumWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LPTXLeap TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ORMPOramed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025PRPHProPhase LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025EQEquilliumWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LPTXLeap TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ORMPOramed PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025PRPHProPhase LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCFRXContraFectN/AN/AN/AN/A($19.92) per shareN/AEQEquillium$16.55M4.64N/AN/A$0.54 per share2.39LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AORMPOramed Pharmaceuticals$2M46.66N/AN/A$3.61 per share0.63PRPHProPhase Labs$6.77M2.52N/AN/A$0.25 per share1.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/AEQEquillium-$8.07M-$0.56N/AN/AN/AN/A-139.56%-90.56%11/12/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.58N/AN/AN/AN/A-237.65%-155.38%11/12/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.35N/AN/AN/AN/A-19.37%-18.28%11/6/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-262.42%-76.48%11/12/2025 (Estimated)Latest EQ, CFRX, PRPH, LPTX, and ORMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025EQEquillium-$0.14N/AN/AN/AN/AN/A11/12/2025Q3 2025LPTXLeap Therapeutics-$0.24N/AN/AN/AN/AN/A11/6/2025N/AORMPOramed Pharmaceuticals-$0.04N/AN/AN/AN/AN/A8/14/2025Q2 2025EQEquillium-$0.14-$0.16-$0.02-$0.16N/AN/A8/14/2025Q2 2025LPTXLeap Therapeutics-$0.29-$0.40-$0.11-$0.40N/AN/A8/14/2025Q2 2025ORMPOramed Pharmaceuticals-$0.04-$0.05-$0.01$0.31N/AN/A8/13/2025Q2 2025PRPHProPhase Labs-$0.15-$0.11+$0.04-$0.11$3.55 million$1.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCFRXContraFectN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCFRXContraFectN/A0.530.53EQEquilliumN/A1.651.65LPTXLeap TherapeuticsN/A1.341.34ORMPOramed PharmaceuticalsN/A26.8226.81PRPHProPhase Labs0.200.960.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCFRXContraFect7.85%EQEquillium27.05%LPTXLeap Therapeutics30.46%ORMPOramed Pharmaceuticals12.73%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipCFRXContraFect0.62%EQEquillium31.60%LPTXLeap Therapeutics7.50%ORMPOramed Pharmaceuticals17.80%PRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCFRXContraFect2310.70 million10.64 millionNot OptionableEQEquillium4059.50 million41.47 millionNot OptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableORMPOramed Pharmaceuticals1041.00 million33.71 millionOptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableEQ, CFRX, PRPH, LPTX, and ORMP HeadlinesRecent News About These CompaniesProPhase Labs Inc. Advances Esophageal Cancer Screening with Acceptance of BE-Smart™ Study for Publication3 hours ago | quiverquant.comQProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology4 hours ago | globenewswire.comProPhase Labs files to sell 226.31M shares of common stock for holdersOctober 21 at 12:54 AM | msn.comProPhase Labs Signs Sales Agreement with WestPark CapitalOctober 15, 2025 | tipranks.comCritical Biotech giant files Chapter 11 for 3 COVID labs, eyes Bitcoin treasury as lifelineSeptember 23, 2025 | thestreet.comProPhase announces three COVID-19 testing companies filed for reorganizationSeptember 23, 2025 | msn.comBiotech firm files Chapter 11 bankruptcy for 3 labs, explores crypto planSeptember 23, 2025 | msn.comPROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVESeptember 23, 2025 | globenewswire.comProPhase Labs continues exploration of crypto treasury strategySeptember 22, 2025 | msn.comProPhase Continues its Exploration of a Crypto Treasury StrategySeptember 22, 2025 | globenewswire.comProPhase Labs stockholders approval all proposals at Special MeetingSeptember 12, 2025 | msn.comProPhase Labs, Inc.: ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In FavorSeptember 12, 2025 | finanznachrichten.deProPhase Labs Stockholders Approve Strategic Initiatives and Increase Authorized Shares at Special MeetingSeptember 12, 2025 | quiverquant.comQProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In FavorSeptember 12, 2025 | globenewswire.comProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025September 3, 2025 | markets.businessinsider.comProPhase Labs Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025September 3, 2025 | globenewswire.comProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | seekingalpha.comProPhase Labs files definitive proxy statement for special meetingAugust 20, 2025 | msn.comProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of ShareholdersAugust 19, 2025 | globenewswire.comProPhase Labs Inc (PRPH) Q2 2025 Earnings Call Highlights: Strategic Moves and Future ProspectsAugust 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 REITs to Watch as Rate Cuts Ignite a Real Estate Super CycleBy Gabriel Osorio-Mazilli | October 7, 2025FICO’s Big Dip Could Be the Best Buying Chance of the YearBy Gabriel Osorio-Mazilli | October 13, 2025This Less-Hyped Tech Stock Could Be the Key to the Next AI WaveBy Gabriel Osorio-Mazilli | October 17, 2025Why These 2 Crypto ETFs Could Soar After the Sell-OffBy Jordan Chussler | October 21, 20255 Stocks and ETFs to Weather Volatility as Trade Tensions RiseBy Ryan Hasson | October 13, 2025EQ, CFRX, PRPH, LPTX, and ORMP Company DescriptionsContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Equillium NASDAQ:EQ$1.29 -0.09 (-6.52%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Leap Therapeutics NASDAQ:LPTX$0.46 -0.03 (-5.89%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Oramed Pharmaceuticals NASDAQ:ORMP$2.28 -0.06 (-2.74%) As of 10:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.ProPhase Labs NASDAQ:PRPH$0.41 -0.10 (-19.75%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Can the SharkNinja Rally Continue? Analysts Think So Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
